c-Fms
CSF-1 receptor; colony stimulating factor 1 receptor; CSF-1R; CSF1R
c-FMS (CSF1R, CSF-1R) is a receptor protein-tyrosine kinase of the platelet-derived growth factor receptor (PDGFR) family. c-FMS is the cell surface receptor for IL-34 and CSF1. c-FMS has important roles in haematopoiesis, regulation of proliferation, cell survival and maturation of microglia and monocytes, as well as in controlling the overall immune response.
c-FMS is specifically expressed in osteoclasts and myelomonocytic-lineage cells, such as monocytes and macrophages, and the activation of c-FMS signaling promotes the proliferation or differentiation of these cells. It also promotes the production of inflammatory mediators, such as tumor necrosis factor-alpha (TNF-α) and interleukin 6 (IL6).
All Product Categories
-
c-Fms Related Products (141)
Related Products (141)
-
Recombinant Proteins (23)
-
Antibodies (8)
-
CSF1R-IN-7
0 ImagesCat. No.: HY-147608CAS No.: 2738328-56-6CSF1R-IN-7 (Formula I) is a CSF-1R inhibitor. CSF1R-IN-7 can be used for Alzheimer’s disease research.
-
CSF1R-IN-9
0 ImagesCat. No.: HY-147610CAS No.: 2765301-84-4CSF1R-IN-9 (Compound 46) is a CSF-1R inhibitor with an IC50 of 0.028 μM.
-
CSF1R-IN-17
0 ImagesCat. No.: HY-155550CAS No.: 3034870-19-1CSF1R-IN-17 (compound 9) is a potent and selective CSF1R antagonist, with an IC50 of 0.2 nM. CSF1R-IN-17 can inhibit osteoclast differentiation.
-
CSF1R-IN-14
0 ImagesCat. No.: HY-147617CAS No.: 2361378-89-2CSF1R-IN-14 is an isoindolinone derivative compound. CSF1R-IN-14 is a potent inhibitor of CSF1R. Colony stimulating factor 1 (CSF-1, also known as macrophage colony stimulating factor, M-CSF) is an important growth factor that controls bone marrow progenitor cells, monocytes, macrophages, and giants. CSF1R-IN-14 has the potential for the research of cancer diseases (extracted from patent WO2019134662A1, compound 1).
-
CSF1R-IN-23
0 ImagesCat. No.: HY-158148CAS No.: 2935480-17-2CSF1R-IN-23 (Compound 7dri) is a selective inhibitor for colony-stimulating factor-1 receptor (CSF1R), with IC50 of 36.1 nM. CSF1R-IN-23 serves as antineuroinflammatory agent in mouse model. CSF1R-IN-23 is blood brain barrier (BBB) permeable.
-
CSF1R-IN-4
0 ImagesCat. No.: HY-144040CAS No.: 2716185-86-1CSF1R-IN-4 is a potent inhibitor of CSF1R. CSF-1R is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. CSF1R-IN-4 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF1R-IN-4 has the potential for the research of cancer disease (extracted from patent WO2021197276A1, compound 104).
-
Ataquimast
0 ImagesCat. No.: HY-108162ACAS No.: 182316-31-0
-
Balugrastim
0 ImagesCat. No.: HY-P99458CAS No.: 527698-09-5Synonyms: CG 10639
-
c-Fms-IN-12
0 ImagesCat. No.: HY-147864CAS No.: 2145102-33-4c-Fms-IN-12 (Compound 4g) is an FMS kinase inhibitor. c-Fms-IN-12 can also inhibits c-KIT. c-Fms-IN-12 is a potential broad-spectrum anticancer agent against multiple cancer types. c-Fms-IN-12 induces A549 cell apoptosis.
-
CSF1R-IN-26
0 ImagesCat. No.: HY-168954CSF1R-IN-26 (Compound III-1) is the inhibitor for CSF-1R with an IC50 of 20.07 nM. CSF1R-IN-26 promotes the polarization of M2 macrophages to M1 macrophages, thereby inducing apoptosis in MC-38 cancer cell. CSF1R-IN-26 inhibits the activation of AKT/ERK/STAT3 signaling pathway. CSF1R-IN-26 reconstructs the tumor immune microenvironment and exhibits antitumor activity in mouse models. CSF1R-IN-26 exhibits pharmacokinetics characteristics in SD rats with a half-life 1.86 hours, and an oral bioavailability of 79.22%.
-
cFMS Receptor Inhibitor IV
0 ImagescFMS Receptor Inhibitor IV (Compound 42) is a potent cFMS inhibitor with an IC50 of 0.017 μM.
-
JNJ-28312141 hydrochloride
0 ImagesCat. No.: HY-13496ACAS No.: 1149939-55-8JNJ-28312141 hydrochloride is an inhibitor for colony-stimulating factor-1 receptor (CSF-1R or FMS), with an IC50 of 0.69 nM. JNJ-28312141 hydrochloride inhibits proliferation of BDBM, MV-4-11, M-o7e, TF-1 with an IC50s of 2.6, 21, 41 and 150 nM, respectively. JNJ-28312141 hydrochloride exhibits anti-inflammatory activity in mouse arthritis model.
-
CSF1R-IN-25
0 ImagesCat. No.: HY-158363CAS No.: 2070864-23-0CSF1R-IN-25 (compound 36) is an orally effective CSF1R inhibitor. CSF1R-IN-25 can be used to study cancer, inflammation, and neurodegeneration.
-
CSF1R-IN-19
0 ImagesCat. No.: HY-157422CAS No.: 1819989-27-9CSF1R-IN-19 is a potent inhibitor of CSF1R. CSF1R-IN-19 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF1R-IN-19 has the potential for the research of cancer.
-
Axl/Mer/CSF1R-IN-1
0 ImagesCat. No.: HY-153012CAS No.: 2394874-60-1Axl/Mer-IN-1 (Compound 1) is an Axl/Mer receptor tyrosine kinase (Axl/Mer RTK) and CSF1R inhibitor with Kds of <0.1 μM.
-
Dovitinib-d8
0 ImagesCat. No.: HY-50905SCAS No.: 1246819-84-0
-
CSF1R-IN-8
0 ImagesCat. No.: HY-147609CAS No.: 2765301-60-6CSF1R-IN-8 (Compound 22) is a CSF-1R inhibitor with an IC50 of 0.012 μM.
-
Pimicotinib hydrochloride
0 ImagesCat. No.: HY-153920ACAS No.: 2866305-19-1Synonyms: ABSK021 hydrochloridePimicotinib (ABSK021) hydrochloride is a selective and orally active CSF1R inhibitor with an IC50 value of 19.48 nM (determined by inhibiting ADP production). Pimicotinib hydrochloride exhibits anti-tumor activity.
-
CSF1R-IN-22
0 ImagesCat. No.: HY-162415CAS No.: 2760585-35-9CSF1R-IN-22 (Compound C19) is an orally effective CSF-1R selective inhibitor (IC50<6 nM). CSF1R-IN-22 enhances the secretion of CXCL9 from M2 macrophages, increases CD8+ T cell infiltration. CSF1R-IN-22 boosts anti-tumor immune responses of anti-PD-1, and induces apoptosis in tumor cells. CSF1R-IN-22 can effectively reprogram M2-like TAMs (tumor-associated macrophages) to the M1 phenotype and reshape the TME by inducing the recruitment of CD8+ T cells into tumors and reducing the infiltration of immunosuppressive Tregs and MDSCs.
-
CSF1R-IN-13
0 ImagesCat. No.: HY-147616CAS No.: 2361556-61-6CSF1R-IN-13 is a potent inhibitor of CSF1R. Colony stimulating factor 1 (CSF-1, also known as macrophage colony stimulating factor, M-CSF) is an important growth factor that controls bone marrow progenitor cells, monocytes, macrophages, and giants. CSF1R-IN-13 has the potential for the research of cancer diseases (extracted from patent WO2019134661A1, compound 32).
